Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15867298rdf:typepubmed:Citationlld:pubmed
pubmed-article:15867298lifeskim:mentionsumls-concept:C0009319lld:lifeskim
pubmed-article:15867298lifeskim:mentionsumls-concept:C0007452lld:lifeskim
pubmed-article:15867298lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:15867298lifeskim:mentionsumls-concept:C0003209lld:lifeskim
pubmed-article:15867298lifeskim:mentionsumls-concept:C1515999lld:lifeskim
pubmed-article:15867298lifeskim:mentionsumls-concept:C0286762lld:lifeskim
pubmed-article:15867298pubmed:issue5lld:pubmed
pubmed-article:15867298pubmed:dateCreated2005-5-3lld:pubmed
pubmed-article:15867298pubmed:abstractTextMilk kappa-casein-derived glycomacropeptide has immunomodulatory and bacterial toxin binding effects. The intestinal anti-inflammatory activity of glycomacropeptide was assessed in trinitrobenzenesulfonic acid-induced colitis in rats. Rats were administered glycomacropeptide daily starting either 2 d before (pretreatment) or 3 h after (post-treatment) colitis induction. Pretreatment with glycomacropeptide had a dose-dependent anti-inflammatory effect, characterized by lower body weight loss, decreased anorexia (57%), colonic damage (65%), and weight to length ratio (32%), as well as a reduction in colonic alkaline phosphatase activity (42%) and interleukin 1, trefoil factor 3, and inducible nitric oxide synthase mRNA levels (P < 0.05). The mechanism of action of glycomacropeptide is unknown but is consistent with an inhibition of the activation of immune cells. The magnitude of the anti-inflammatory effect was generally comparable to that of sulfasalazine, an established drug used in the treatment of inflammatory bowel disease. Bovine glycomacropeptide may play a role in the management of patients with inflammatory bowel disease.lld:pubmed
pubmed-article:15867298pubmed:languageenglld:pubmed
pubmed-article:15867298pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:citationSubsetIMlld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867298pubmed:statusMEDLINElld:pubmed
pubmed-article:15867298pubmed:monthMaylld:pubmed
pubmed-article:15867298pubmed:issn0022-3166lld:pubmed
pubmed-article:15867298pubmed:authorpubmed-author:ZarzueloAnton...lld:pubmed
pubmed-article:15867298pubmed:authorpubmed-author:Martínez-Augu...lld:pubmed
pubmed-article:15867298pubmed:authorpubmed-author:Sánchez de...lld:pubmed
pubmed-article:15867298pubmed:authorpubmed-author:DaddaouaAbdel...lld:pubmed
pubmed-article:15867298pubmed:authorpubmed-author:PuertaVíctorVlld:pubmed
pubmed-article:15867298pubmed:authorpubmed-author:SuárezMaría...lld:pubmed
pubmed-article:15867298pubmed:issnTypePrintlld:pubmed
pubmed-article:15867298pubmed:volume135lld:pubmed
pubmed-article:15867298pubmed:ownerNLMlld:pubmed
pubmed-article:15867298pubmed:authorsCompleteYlld:pubmed
pubmed-article:15867298pubmed:pagination1164-70lld:pubmed
pubmed-article:15867298pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:meshHeadingpubmed-meshheading:15867298...lld:pubmed
pubmed-article:15867298pubmed:year2005lld:pubmed
pubmed-article:15867298pubmed:articleTitleBovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis.lld:pubmed
pubmed-article:15867298pubmed:affiliationDepartment of Biochemistry and Molecular Biology, School of Pharmacy, University of Granada, Spain.lld:pubmed
pubmed-article:15867298pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15867298pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15867298lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15867298lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15867298lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15867298lld:pubmed